Upregulation of ubiquitin-conjugating enzyme E2T (UBE2T) predicts poor prognosis and promotes hepatocellular carcinoma progression

References

• Chen J, Zhou J, Fu H, et al. Upregulation of oxidative stress-responsive 1(OXSR1) predicts poor prognosis and promotes hepatocellular carcinoma progression. Bioengineered. 2020;11:958–971.
   PubMed Web of Science ®Google Scholar
• Chen VL, Sharma P. Role of biomarkers and biopsy in hepatocellular carcinoma. Clin Liver Dis. 2020;24:577–590.
   PubMed Web of Science ®Google Scholar
• Li J, Zhu Y. Recent advances in liver cancer stem cells: non-coding RNAs, oncogenes and oncoproteins. Front Cell Dev Biol. 2020;8:548335.
   PubMed Web of Science ®Google Scholar
• Wu X, Liu G, Liu R, et al. Expression of ubiquitin-conjugating enzyme E2T in colorectal cancers and clinical implications. Oncol Lett. 2020;20:275.
   PubMed Web of Science ®Google Scholar
• Zhu X, Li T, Niu X, et al. Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer. Oncol Lett. 2020;20:44.
   PubMed Web of Science ®Google Scholar
• Wu M, Li X, Huang W, et al. Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53. Clin Res Hepatol Gastroenterol. 2020;101493. DOI:10.1016/j.clinre.2020.06.018
   Web of Science ®Google Scholar
• Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021 Apr;70(4):784-795.
   Google Scholar
• Kipkeeva F, Muzaffarova T, Korotaeva A, et al. MicroRNA in gastric cancer development: mechanisms and biomarkers. Diagnostics. 2020;10:891.
   Web of Science ®Google Scholar
• Sa R, Song H, Wei M, et al. MiR-616 plays oncogenic role in hepatocellular carcinoma progression through suppressing PTEN expression and activating PI3K/AKT pathway. Artif Cells Nanomed Biotechnol. 2020;48:728–734.
   PubMed Web of Science ®Google Scholar
• Liu LP, Yang M, Peng QZ, et al. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun. 2017;493:20–27.
   PubMed Web of Science ®Google Scholar
• Wei X, You X, Zhang J, et al. MicroRNA-1305 inhibits the stemness of LCSCs and tumorigenesis by repressing the UBE2T-dependent Akt-signaling pathway. Mol Ther Nucleic Acids. 2019;16:721–732.
   PubMedGoogle Scholar
• Fang SS, Guo JC, Zhang JH, et al. A P53-related microRNA model for predicting the prognosis of hepatocellular carcinoma patients. J Cell Physiol. 2020;235:3569–3578.
   PubMed Web of Science ®Google Scholar
• Shi L, Shang X, Nie K, et al. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma. J Clin Pathol. 2020. DOI:10.1136/jclinpath-2020-206979.
   Web of Science ®Google Scholar
• Wang X, Qiao J, Wang R. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in Hepatocellular Carcinoma. Biosci Rep. 2020;40. DOI:10.1042/BSR20203263
   Web of Science ®Google Scholar
• Singh G, Yoshida EM, Rathi S, et al. Biomarkers for hepatocellular cancer. World J Hepatol. 2020;12:558–573.
   PubMed Web of Science ®Google Scholar
• Yin H, Wang X, Zhang X, et al. UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation. Cancer Lett. 2020;494:121–131.
   PubMed Web of Science ®Google Scholar
• Hu W, Xiao L, Cao C, et al. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway. Oncotarget. 2016;7:15161–15172.
   PubMedGoogle Scholar
• Huang J. Current developments of targeting the p53 signaling pathway for cancer treatment. Pharm Ther. 2020;107720. ttps://pubmed.ncbi.nlm.nih.gov/33130194/
   PubMed Web of Science ®Google Scholar
• Yu Z, Jiang X, Qin L, et al. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 2021;40:1027–1042.
   PubMed Web of Science ®Google Scholar
• Ho NPY, Leung CON, Wong TL, et al. The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression. Cell Death Dis. 2021;12:148.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhu Z, Li W, et al. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 2020;39:222.
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–1207.
   PubMed Web of Science ®Google Scholar
• Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang G, Yu Y, et al. MicroRNA‑490‑3p suppresses the proliferation and invasion of hepatocellular carcinoma cells via targeting TMOD3. Oncol Lett. 2020;20(4):95.
   PubMed Web of Science ®Google Scholar
• Du F, Li Z, Zhang G, et al. SIRT2, a direct target of miR-212-5p, suppresses the proliferation and metastasis of colorectal cancer cells. J Cell Mol Med. 2020;24:9985–9998.
   PubMed Web of Science ®Google Scholar
• Chen FF, Sun N, Wang Y, et al. miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells. J Cell Physiol. 2020;235:7273–7282.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Huang Y, et al. Long non-coding RNA MIF-AS1 promotes gastric cancer cell proliferation and reduces apoptosis to upregulate NDUFA4. Cancer Sci. 2018;109:3714–3725.
   PubMed Web of Science ®Google Scholar
• Lv ZD, Yang DX, Liu XP, et al. MiR-212-5p suppresses the epithelial-mesenchymal transition in triple-negative breast cancer by targeting Prrx2. Cell Physiol Biochem. 2017;44:1785–1795.
   PubMedGoogle Scholar
• Deng JH, Zheng GY, Li HZ, et al. MiR-212-5p inhibits the malignant behavior of clear cell renal cell carcinoma cells by targeting TBX15. Eur Rev Med Pharmacol Sci. 2019;23:10699–10707.
   PubMed Web of Science ®Google Scholar